Please use this identifier to cite or link to this item:
|Title:||Beta2-microglobulin removal and plasma albumin levels with high cut-off hemodialysis.||Austin Authors:||Haase, M;Bellomo, Rinaldo ;Baldwin, Ian C ;Haase-Fielitz, Anja;Fealy, Nigel G ;Morgera, Stanislao;Goehl, Hermann;Storr, M;Boyce, Neil;Neumayer, H-H||Affiliation:||Intensive Care Research, Austin Hospital, University of Melbourne, Australia
|Issue Date:||1-May-2007||Publication information:||The International Journal of Artificial Organs; 30(5): 385-92||Abstract:||beta2-microglobulin (beta2MG) is pivotal to the pathogenesis of dialysis-related amyloidosis. We compared the effects of high cut-off hemodialysis (HCO-HD) with those of standard high-flux hemodialysis (HF-HD) regarding the concentration and clearance of beta2MG and albumin.We enrolled ten patients with acute renal failure in a double-blind, cross-over, randomized controlled trial.Each patient received four hours of HCO-HD (estimated in vivo cutoff 50-60 kDa) and four hours of HF-HD (estimated in vivo cutoff 15-20 kDa) in random order. Statistical methods and outcome measures: As data lacked normal distribution, we used nonparametric statistical analysis. Plasma and dialysate concentrations of beta2MG and albumin were measured at baseline and after four hours of each study treatment.We found significantly greater diffusive beta2MG clearances for HCO-HD compared to HF-HD (at the start: 71.8 ml/min vs. 5.1 ml/min; P=0.008 and at the end: 68.8 ml/min vs. 5.7 ml/min; P=0.008). We found a reduction in plasma beta2MG concentrations of -31.6% during HCO-HD compared to an increase by 25.7% during HF-HD; P=0.008. At baseline (HCO-HD: 26.0 g/L vs. HF-HD: 26.5 g/L), and at the end of both treatments, plasma albumin concentrations were comparable (HCO-HD: 25.5 g/L vs. HF-HD: 26.5 g/L; P=0.25). During HCO-HD, albumin clearance was 1.9 ml/min at the start and decreased significantly to 0.8 ml/min at the end; P=0.008. HF-HD had an albumin clearance of 0.01 ml/min.HCO-HD was more effective in decreasing plasma beta2MG concentrations than standard HF-HD and did not reduce plasma albumin levels. Further studies of HCO-HD in the treatment of dialysis-related beta2MG accumulation appear warranted.||Gov't Doc #:||17551901||URI:||http://ahro.austin.org.au/austinjspui/handle/1/10389||URL:||https://pubmed.ncbi.nlm.nih.gov/17551901||Type:||Journal Article||Subjects:||Acute Kidney Injury.blood.therapy
|Appears in Collections:||Journal articles|
Show full item record
checked on Dec 8, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.